ZVRA Zevra Therapeutics, Inc. Common Stock
XNAS
10.48
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ZVRA
$10.48
—
Key stats
$10.48
- 52-Week Range
- $8.01 – $15.04
- YTD
- +25.62%
- IV Rank (30D)
- 41.2
- Straddle Price
- $4.28
- P/C Vol Ratio
- 1.96
- Market Cap
- $0.6B
- Open
- $10.36
- Day Range
- $10.24 – $10.61
- Volume
- 75,963
- Prev Close
- $10.36
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.16 |
| Cost of Equity (CAPM) | 11.55% (VRP-adj) |
| WACC | 11.51% |
| Volatility Risk Premium | +121.8pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 15.9% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 15 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | 26.6% |
| Book / Price | 35.8% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 95.5% |
| FCF Margin (TTM) | 24.0% |
| Debt / Equity | 0.00 |
| Quality Score | 6/6 — compounder (15y DCF) |
| Market-Implied Growth | +5.9% (reverse-DCF on current price) |
| SMA 50 | $11.38 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $10.71 |
| Bollinger Width / SMA20 | 168.8% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$25.10
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $42.76 | 30% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $40.10 | 14% | median 39.6× · 3 peers |
| Peer EV/EBITDA | $16.90 | 14% | median 19.0× · 3 peers |
| Peer P/B | $12.87 | 3% | median 3.5× · 3 peers |
| Peer P/S | $9.72 | 9% | median 3.8× · 3 peers |
| Market Anchor (SMA50) | $11.38 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $10.08 | 30% | 25 strikes · skew +0.20 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.6B
- Employees
- 61
- List Date
- 2015-04-16
- CIK
- 0001434647
- Next Earnings
- 2026-11-03 (After-Close)
- EPS Forecast
- $0.14 (3 est.)
- Headquarters
- Boston, MA
- Homepage
- https://www.zevra.com
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | -15.23% | -10.50% | 7.91% | -5.94% |
| Feb | -- | 13.09% | 4.71% | -4.59% | 4.40% |
| Mar | 0.73% | -18.08% | 2.18% | 2.53% | -3.16% |
| Apr | -2.70% | -11.24% | 0.14% | 8.08% | -1.43% |
| May | -4.36% | 1.09% | 11.91% | 15.09% | 5.93% |
| Jun | -0.39% | 0.41% | 1.73% | 24.80% | 6.64% |
| Jul | -3.94% | 43.90% | 24.13% | -31.97% | 8.03% |
| Aug | 3.47% | 21.43% | -18.36% | 16.76% | 5.83% |
| Sep | -10.41% | -4.93% | 4.51% | -9.04% | -4.97% |
| Oct | -5.08% | 18.98% | 7.95% | 2.85%* | 6.17% |
| Nov | 6.97% | 11.07% | -17.43% | -- | 0.20% |
| Dec | 32.06% | -13.84% | 7.43% | -- | 8.55% |
| Total | 11.49% | 33.83% | 10.72% | 21.77% | 19.45% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $10.67
SMA 50: $11.37
SMA 200: $10.71
Current: $10.45
EMA 12: $10.51
EMA 26: $10.82
MACD: -0.3074 | Signal: -0.0047
BEARISH
ADX (14): 16.45
RANGE
+DI: 21.74
−DI: 26.96
Momentum Oscillators
RSI (14): 44.05
NEUTRAL
Stoch %K: 36.21
Stoch %D: 29.31
Williams %R: -62.35
Volume & Volatility
BB Upper: $11.60
BB Lower: $9.73
NEUTRAL
OBV: 39,588,560
Vol SMA 20: 836,612
Vol ROC: -84.48%
ATR: $0.45
True Range: $0.37
HV 20: 57.6%
HV 30: 48.4%
HV 60: 50.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical indicators suggesting a neutral trend
- Recent news headlines mix of positive and negative sentiment
Primary Risks:
- Volatility risk due to low historical volatility
- Options market pricing in significant move, but uncertainty around direction
Investment Thesis: ZVRA's recent performance is characterized by a lack of strong directional momentum. While the stock has not experienced a significant price move recently, its technical indicators suggest a neutral trend. The options market is pricing in a potential $2.67 move by expiration, which could be driven by either positive or negative news.
Recent News Sentiment Impact: The recent news headlines have been mixed, with both positive and negative sentiment expressed. The company's regulatory submission for arimoclomol in the European Union (EU) was met with negative sentiment, while other news articles had a more neutral tone.
Technical Analysis
Trend Direction:
- Short-term: NEUTRAL
- Medium-term: NEUTRAL
- Long-term: BEARISH (based on SMA 200)
Support/Resistance Levels: The stock is trading around the SMA 20 ($10.99), with resistance at the upper Bollinger Band ($13.20). The lower Bollinger Band ($8.79) serves as support.
Momentum Signals:
- RSI: NEUTRAL (48.84)
- MACD: BEARISH (signal line above, histogram below)
- Bollinger Bands: NEUTRAL (price not touching upper or lower band)
Volume Analysis: The volume is relatively low, with a volume rate of change indicating a decrease in trading activity.
News & Sentiment Analysis
Recent Headlines Summary:
- Zevra Therapeutics provides update on regulatory submission for arimoclomol in the EU (negative sentiment)
- XOMA Royalty reports 2025 financial results and highlights recent business achievements (neutral sentiment)
- Zevra Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) (neutral sentiment)
- Zevra Therapeutics enters agreement to sell its rare pediatric disease priority review voucher for $150 million (positive sentiment)
- Zevra Therapeutics announces organizational changes (positive sentiment)
Sentiment Assessment: The overall news sentiment is NEUTRAL, with a mix of positive and negative headlines.
Catalyst Identification: The upcoming regulatory submission for arimoclomol in the EU could be a catalyst for the stock's price movement.
Market Narrative: The recent news headlines suggest that the company's focus on regulatory submissions and business developments may not have significantly impacted the stock's price yet. The market narrative is NEUTRAL, with no clear direction or trend emerging.
Risk & Volatility Assessment
Risk Assessment:
- Beta: 0.78 (low risk relative to SPY)
- Alpha: 0.24 (positive alpha suggests outperformance)
- Correlation: 0.15 (low correlation with SPY)
Volatility Regime: The stock is trading in a low volatility regime, with the historical volatility metrics indicating relatively stable price movements.
Options Market Signals:
- IV Rank: 17.6% (low volatility, historically low IV)
- Put/call volume ratio: 0.19 (bullish sentiment)
- Open interest: 316 calls vs 21 puts (more buying pressure)
Downside Protection: The stock's recent performance suggests that it may be able to absorb some market downturns due to its relatively low beta.
Market Context & Positioning
Sector Performance: ZVRA is trading in the pharmaceutical sector, which has been experiencing volatility and uncertainty recently.
Institutional Activity: The options market suggests institutional buying pressure, but the volume flow is relatively low, indicating that institutions are not actively participating in the current price action.
Correlation Analysis: The stock's correlation with SPY is low, suggesting that it may be a good candidate for those looking to diversify their portfolios.
Relative Valuation: ZVRA's relative valuation suggests that it may be slightly undervalued compared to its peers and the overall market.
Key Levels & Action Items
Critical Price Levels:
- Support: SMA 20 ($10.99)
- Resistance: Upper Bollinger Band ($13.20)
Breakout/Breakdown Levels: The stock needs to break above the upper Bollinger Band or below the lower Bollinger Band to generate significant price movement.
Time-Sensitive Catalysts: The upcoming regulatory submission for arimoclomol in the EU could be a catalyst for the stock's price movement.
Risk Management: Given the low volatility and relatively stable price movements, it may be reasonable to consider increasing exposure or buying calls with a moderate risk tolerance. However, caution is advised due to the uncertainty surrounding the regulatory submission and potential market downturns.
Generated
News
All ZVRA news →
Earnings History
11 of 12 under expected move
Avg Expected Move
18.80%
Avg Actual Move
4.53%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-15 | Pre-Market | 20.33% | 3.07% | 0.15x | Within |
| 2023-08-14 | Pre-Market | 10.58% | 3.85% | 0.36x | Within |
| 2023-11-07 | Pre-Market | 17.11% | 3.51% | 0.21x | Within |
| 2024-03-28 | Pre-Market | 25.25% | 2.36% | 0.09x | Within |
| 2024-08-08 | After-Close | 12.86% | 10.55% | 0.82x | Within |
| 2024-11-12 | Pre-Market | 13.39% | 4.35% | 0.32x | Within |
| 2025-04-07 | Pre-Market | 26.99% | 0.14% | 0.01x | Within |
| 2025-08-12 | After-Close | 17.64% | 19.81% | 1.12x | Exceeded |
| 2025-11-05 | Pre-Market | 18.90% | 2.86% | 0.15x | Within |
| 2026-03-09 | Pre-Market | 28.67% | 1.56% | 0.05x | Within |
| 2026-05-06 | After-Close | 18.00% | 2.22% | 0.12x | Within |
| 2026-08-05 | Pre-Market | 15.92% | 0.10% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ZVRA Options Activity & IV Rank
ZVRA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 100.2%
7-DTE IV: —
Expected Move: $4.28
7-DTE Move: $4.28
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 99
Put Volume: 194
P/C Volume: 1.96
BEARISH
Call OI: 3,742
Put OI: 736
P/C OI: 0.197
Total OI: 4,478
ATM Options Pricing
ATM Call: $2.38
ATM Put: $1.90
Call %: 22.7%
Put %: 18.1%
Chain Summary
Chain Volume: 9,616
Chain OI: 75,869
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 36th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
36%
vs own history
GEX tilt
+0.64
OI-weighted, today
Vanna tilt
+0.68
δ-sensitivity to IV
Charm tilt
-0.72
δ-decay vs time
Vanna tilt +0.68: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.72: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 30 ATM contracts, 12k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 183.0% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)41.2MediumOct 22
Straddle Price (30 DTE)$4.28Oct 22
Beta Analysis
Risk Metrics
Beta: 0.9090
Alpha: 2.41%
Correlation: 0.1934
R-Squared: 3.7%
Stock Volatility: 60.0%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own ZVRA
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $1.3M | #2794 of 3716 | -84.7% | 13F | |
| Citadel Hedge fund Ken Griffin | $174K | #5561 of 6285 | -98.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $5K | #4217 of 4729 | -52.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ZVRA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 58,695,348 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$39.03M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $10.89M | 27.91% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $9.40M | 24.09% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $4.65M | 11.92% | 2026-06-30 |
| 4 | Susquehanna International Group, LLP Custodian | $4.51M | 11.54% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $2.88M | 7.39% | 2026-06-30 |
| 6 | Caption Management, LLC | $2.87M | 7.35% | 2026-06-30 |
| 7 | TUDOR INVESTMENT CORP ET AL | $2.60M | 6.67% | 2026-06-30 |
| 8 | IMC-Chicago, LLC Custodian | $1.22M | 3.13% | 2026-06-30 |
8 filers$61.82M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $57.44M | 92.92% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $1.66M | 2.69% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $986.59K | 1.60% | 2026-06-30 |
| 4 | SABBY MANAGEMENT, LLC | $612.32K | 0.99% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $319.78K | 0.52% | 2026-06-30 |
| 6 | Susquehanna International Group, LLP Custodian | $312.61K | 0.51% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $305.44K | 0.49% | 2026-06-30 |
| 8 | IMC-Chicago, LLC Custodian | $177.82K | 0.29% | 2026-06-30 |
ZVRA Insider Trading (Form 4)
Latest: 2026-10-13Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | Neil F. McFarlane | President and CEO | Mixed | +30,000 | $11.25 | -$224.9K | EDGAR |
| 2026-08-17 | Rahsaan Thompson | Chief Legal & Compliance | Sell (S) | −42,666 | $11.13 | -$474.8K | EDGAR |
| 2026-08-12 | Corey Michael Watton | Director | Mixed | — | $8.11 | -$77.2K | EDGAR |
| 2026-06-23 | Rahsaan Thompson | Chief Legal & Compliance | Mixed | +32,110 | $12.68 | -$438.3K | EDGAR |
| 2026-06-18 | Tamara A Favorito | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-06-18 | Alicia Secor | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-06-18 | Corey Michael Watton | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-06-18 | Thomas Anderson | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-06-18 | Douglas W Calder | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-06-18 | Alvin Shih | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-05-29 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | Grant (A) | +60,000 RSU | — | EDGAR | |
| 2026-05-13 | Rahsaan Thompson | Chief Legal & Compliance | Sell (S) | −1,794 | $11.30 | -$20.3K | EDGAR |
| 2026-03-26 | John B Bode | Director | Exer (M) | +78,400 | $4.93 | $386.5K | EDGAR |
| 2026-03-19 | Justin A Renz | CFO | Grant (A) | +300,000 opt | — | EDGAR | |
| 2026-02-10 | Neil F. McFarlane | President and CEO | Mixed | +22,875 | $8.56 | -$125.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ZVRA Insider Holdings
11 insiders · @ $10.45
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Neil F. McFarlane | President and CEO | 437,225 | $4.57M | -$2.14M | 9 | 2026-10-13 |
| 2 | R. LaDuane Clifton | CFO & Treasurer | 143,515 | $1.50M | -$47.3K | 8 | 2026-01-07 |
| 3 | John B Bode | Director | 123,400 | $1.29M | $285.9K | 9 | 2026-03-26 |
| 4 | Joshua Schafer | CCO | 62,278 | $650.8K | -$191.6K | 8 | 2026-02-04 |
| 5 | Rahsaan Thompson | Chief Legal & Compliance | 37,569 | $392.6K | -$1.19M | 8 | 2026-08-17 |
| 6 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | 29,590 | $309.2K | -$61.6K | 7 | 2026-05-29 |
| 7 | Alvin Shih | Director | 20,000 | $209.0K | $157.8K | 5 | 2026-06-18 |
| 8 | Thomas Anderson | Director | 20,000 | $209.0K | $116.8K | 6 | 2026-06-18 |
| 9 | Adrian W Quartel | Chief Medical Officer | 14,256 | $149.0K | -$40.0K | 2 | 2026-02-02 |
| 10 | Corey Michael Watton | Director | 14,100 | $147.3K | -$126.6K | 10 | 2026-08-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ZVRA Board & Officers
As of SEC filings through Oct 13, 2026Directors 8
- Tamara A Favorito · since Aug 18, 2021
- Corey Michael Watton · since Apr 25, 2023
- Douglas W Calder · since Apr 25, 2023
- John B Bode · since Apr 25, 2023
- Thomas Anderson · since Aug 7, 2023
- Neil F. McFarlane · since Oct 10, 2023
- Alvin Shih · since Jan 20, 2024
- Alicia Secor · since Dec 2, 2025
Officers 5
- Neil F. McFarlane · President and CEO · since Oct 10, 2023
- Justin A Renz · CFO · since Mar 18, 2026
- Rahsaan Thompson · Chief Legal & Compliance · since Jun 21, 2024
- Adrian W Quartel · Chief Medical Officer · since Dec 6, 2024
- Joshua Schafer · Cco · listed since Feb 2026
Changes in the last 10 years (43)
| Mar 18, 2026 | Justin A Renz became CFO |
| Mar 4, 2026 | The company announced the departure of Timothy J. Sangiovanni as SVP, Finance & Corp Controller in an SEC filing |
| Feb 2, 2026 | Joshua Schafer listed as Cco (previously CCO & EVP, Bus. Development) in SEC filings |
| Jan 7, 2026 | R. LaDuane Clifton reported in an SEC filing no longer being CFO & Treasurer |
| Dec 2, 2025 | Alicia Secor became a director |
| Nov 26, 2025 | The company announced the departure of Wendy L Dixon from the board in an SEC filing |
| Feb 3, 2025 | Timothy J. Sangiovanni listed as SVP, Finance & Corp Controller (previously SVP, Corporate Controller) in SEC filings |
| Dec 6, 2024 | Adrian W Quartel became Chief Medical Officer |
| Jul 17, 2024 | R. LaDuane Clifton listed as CFO & Treasurer (previously CFO, Secretary & Treasurer) in SEC filings |
| Jun 21, 2024 | Rahsaan Thompson became Chief Legal & Compliance |
| Jan 20, 2024 | Alvin Shih became a director |
| Oct 10, 2023 | Neil F. McFarlane became a director |
| Oct 10, 2023 | Neil F. McFarlane became President and CEO |
| Aug 7, 2023 | Thomas Anderson became a director |
| May 5, 2023 | The company announced the departure of Richard W Pascoe as Chief Executive Officer in an SEC filing |
| May 3, 2023 | The company announced the departure of Matthew R Plooster from the board in an SEC filing |
| May 3, 2023 | The company announced the departure of Joseph Saluri from the board in an SEC filing |
| Apr 25, 2023 | Wendy L Dixon became a director |
| Apr 25, 2023 | John B Bode became a director |
| Apr 25, 2023 | Douglas W Calder became a director |
| Apr 25, 2023 | Corey Michael Watton became a director |
| Jan 11, 2023 | Timothy J. Sangiovanni listed as SVP, Corporate Controller (previously VP, Corporate Controller) in SEC filings |
| Jan 11, 2023 | Sven Guenther listed as Chief Scientific Officer (previously EVP, Research & Development) in SEC filings |
| Jan 11, 2023 | Richard W Pascoe listed as Chief Executive Officer (previously Executive Chairman) in SEC filings |
| Jan 10, 2023 | Christal M M Mickle no longer listed as a 10% owner in SEC filings |
| Jan 10, 2023 | Christal M M Mickle listed as Chief Product Dev. Officer (previously VP, Operations & Product Dvlp.) in SEC filings |
| Jan 6, 2023 | The company announced the departure of Travis C Mickle from the board in an SEC filing |
| Jan 6, 2023 | The company announced the departure of Travis C Mickle as President & CEO in an SEC filing |
| Jan 6, 2023 | Joshua Schafer became CCO & EVP, Bus. Development |
| Nov 28, 2022 | Christopher Posner became a director |
| Nov 10, 2021 | Richard W Pascoe first listed as Executive Chairman in an SEC filing |
| Aug 18, 2021 | Tamara A Favorito became a director |
| May 10, 2021 | Samuel J Braun became a 10% owner |
| Mar 5, 2020 | Travis C Mickle no longer listed as a 10% owner in SEC filings |
| Sep 13, 2017 | Delaware Street Capital Master Fund, L.P. became a 10% owner |
| Sep 13, 2017 | DSC Managers, L.L.C. became a 10% owner |
| Sep 13, 2017 | DSC Advisors, L.P. became a 10% owner |
| Sep 13, 2017 | DSC Advisors, L.L.C. became a 10% owner |
| Sep 13, 2017 | Andrew G Bluhm became a 10% owner |
| Feb 13, 2017 | Timothy J. Sangiovanni became VP, Corporate Controller |
| Jan 31, 2017 | Sven Guenther listed as EVP, Research & Development (previously Exec VP R&D) in SEC filings |
| Jan 31, 2017 | R. LaDuane Clifton listed as CFO, Secretary & Treasurer (previously Chief Financial Officer) in SEC filings |
| Jan 31, 2017 | Christal M M Mickle listed as VP, Operations & Product Dvlp. (previously VP Prod Dev) in SEC filings |
Not reported recently (14)
- Sven Guenther · Last reported as Chief Scientific Officer in an SEC filing dated Feb 2, 2024
- Christal M M Mickle · Last reported as Chief Product Dev. Officer in an SEC filing dated Feb 2, 2024
- Richard W Pascoe · Last reported as a director in an SEC filing dated Apr 25, 2023
- David S Tierney · Last reported as a director in an SEC filing dated Apr 25, 2023
- Christopher Posner · Last reported as a director in an SEC filing dated Apr 25, 2023
- Samuel J Braun · Last reported as a 10% owner in an SEC filing dated May 17, 2021
- Gordon K Johnson · Last reported as Chief Business Officer in an SEC filing dated Jan 2, 2020
- Danny L Thompson · Last reported as a director in an SEC filing dated Jul 2, 2019
- Delaware Street Capital Master Fund, L.P. · Last reported as a 10% owner in an SEC filing dated Oct 9, 2018
- DSC Managers, L.L.C. · Last reported as a 10% owner in an SEC filing dated Oct 9, 2018
- Andrew G Bluhm · Last reported as a 10% owner in an SEC filing dated Oct 9, 2018
- DSC Advisors, L.L.C. · Last reported as a 10% owner in an SEC filing dated Oct 9, 2018
- DSC Advisors, L.P. · Last reported as a 10% owner in an SEC filing dated Oct 9, 2018
- Daniel L Cohen · Last reported as EVP, Govt. & Public Relations in an SEC filing dated May 17, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ZVRA Proposed Insider Sales (Form 144)
Latest: 2026-10-13
? Form 144 Guide
Last 30d:
1 filing
· $228K notice value
· Last 90d:
2 filings
· $705K notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
RAHSAAN THOMPSON (1, $477K) · NEIL F MCFARLANE (1, $228K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-13 | NEIL F MCFARLANE | Director, Officer | 20,000 | $227.8K | 2026-10-12 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-14 | RAHSAAN THOMPSON | Officer, Secretary | 42,666 | $477.0K | 2026-08-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-08 | JOHN BODE | Director | 10,516 | $156.2K | 2026-07-08 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-11 | Rahsaan Thompson | Officer, Chief Legal & Compliance / Secretary | 36,351 | $404.6K | 2026-05-11 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-16 | RAYMOND L CLIFTON | Officer | 345,428 | $3.41M | 2026-03-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-02-02 | NEIL F MCFARLANE | Director, Officer | 105,625 | $950.6K | 2026-02-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-01-30 | TIMOTHY SANGIOVANNI | Officer | 4,750 | $42.1K | 2026-01-30 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-01-30 | R LaDuane Clifton | Former CFO & Treasurer | 14,000 | $124.0K | 2026-01-30 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-01-30 | RAHSAAN THOMPSON | Officer, Secretary | 4,080 | $36.1K | 2026-01-30 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-01-30 | JOSHUA SCHAFER | Officer | 13,875 | $122.9K | 2026-01-30 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
55 ETFs hold ZVRA
25 shown · $95.44M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $20.8M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.02% | $15.6M | $75.1B | 2026-10-20 |
| 3 | JSMD Janus Henderson Small/Mid Cap Growth Alpha ETF | Janus | 0.79% | $8.1M | $1.0B | 2026-10-20 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $7.3M | — | 2026-09-30 |
| 5 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 1.49% | $6.7M | $452.3M | 2026-10-20 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.04% | $4.8M | $11.0B | 2026-10-20 |
| 7 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $4.0M | — | 2026-10-20 |
| 8 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.03% | $3.9M | $13.7B | 2026-10-20 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $3.8M | — | 2026-09-30 |
| 10 | JSML Janus Henderson Small Cap Growth Alpha ETF | Janus | 0.74% | $2.7M | $363.1M | 2026-10-20 |
| 11 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $2.1M | — | 2026-10-20 |
| 12 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.15% | $1.9M | $1.2B | 2026-10-20 |
| 13 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $1.8M | $13.6B | 2026-10-20 |
| 14 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.7M | — | 2026-10-20 |
| 15 | PTH Invesco Dorsey Wright Healthcare Momentum ETF | Nport | 0.64% | $1.5M | — | 2026-07-31 |
| 16 | VFMF Vanguard U.S. Multifactor ETF | Vanguard | 0.12% | $1.3M | — | 2026-10-20 |
| 17 | SFLO VictoryShares Small Cap Free Cash Flow ETF | Nport | 0.19% | $1.1M | — | 2026-06-30 |
| 18 | SURI Simplify Propel Opportunities ETF | Nport | 1.25% | $966,114 | — | 2026-06-30 |
| 19 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.00% | $887,531 | — | 2026-10-20 |
| 20 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.03% | $857,503 | $3.1B | 2026-10-20 |
| 21 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $802,348 | $97.4B | 2026-10-20 |
| 22 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $713,562 | — | 2026-10-20 |
| 23 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.10% | $707,378 | — | 2026-06-30 |
| 24 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.04% | $692,570 | — | 2026-10-20 |
| 25 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.18% | $488,692 | — | 2026-05-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
11.38
TTM Diluted EPS
$0.92
TTM Revenue
$136.07M
TTM Net Income
$57.90M
TTM Op. Cash Flow
$33.40M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $39.66M | $8.39M | $0.14 | $17.03M |
| Q1 '26 | 2026-03-31 | $36.22M | $37.89M | $0.60 | $6.14M |
| Q4 '25 | 2025-12-31 | $34.12M | $12.16M | $0.19 | $5.52M |
| Q3 '25 | 2025-09-30 | $26.06M | $-544.00K | $-0.01 | $4.71M |
| Q2 '25 | 2025-06-30 | $25.88M | $67.91M | $1.21 | $-3.60M |
| Q1 '25 | 2025-03-31 | $20.40M | $-3.10M | $-0.06 | $-8.22M |
| Q4 '24 | 2024-12-31 | $12.04M | $-35.74M | $-0.69 | $-16.25M |
| Q3 '24 | 2024-09-30 | $3.69M | $-33.23M | $-0.69 | $-18.14M |
| Q2 '24 | 2024-06-30 | $4.45M | $-19.93M | $-0.48 | $-19.11M |
| Q1 '24 | 2024-03-31 | $3.42M | $-16.62M | $-0.40 | $-16.16M |
| Q4 '23 | 2023-12-31 | $12.92M | $-19.89M | $-0.54 | $-16.16M |
| Q3 '23 | 2023-09-30 | $2.90M | $-10.37M | $-0.30 | $-4.63M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
11.38
P/B
2.82
P/S
4.52
EV/EBITDA
11.57
EV/Sales
3.45
ROE
26.6%
ROA
19.1%
Div Yield
0.00%
FCF Yield
5.43%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$614.54M
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.15M
SI % of Float
12.41%
Days to Cover
7.16
Short Vol Ratio
61.4%
Free Float
57.60M
Float %
97.0%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-19